论文信息 - KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy - 字舞流文

KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy

J. Trojan | S. Hollerbach | H. Messmann | R. Stöhr | F. Kullmann | E. Endlicher | M. Dollinger | J. Harder | M. Fuchs | A. Kutscheidt | A. Hartmann | A. Hartmann | M. Troppmann | Helmut Messmann | M. Dollinger | Jan Harder